It would probably be necessary to individualize the recommendation to discontinue SGLT2 inhibitors only in COVID-19 infected patients who present symptoms that predispose to a decrease in blood pressure or vascular volume, to avoid both the deterioration of renal function or DKA. The gene discussed is SLC5A2; the disease is COVID-19.